Compare SWX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWX | IMNM |
|---|---|---|
| Founded | 1931 | 2006 |
| Country | United States | United States |
| Employees | 2453 | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 2.5B |
| IPO Year | 2017 | 2020 |
| Metric | SWX | IMNM |
|---|---|---|
| Price | $81.87 | $21.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $87.40 | $32.80 |
| AVG Volume (30 Days) | 539.5K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 120.29 | 51.40 |
| EPS | ★ 2.49 | N/A |
| Revenue | ★ $5,433,972,000.00 | $6,941,000.00 |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $2.61 | $1,127.34 |
| P/E Ratio | $33.18 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $76.74 | $11.09 |
| 52 Week High | $94.47 | $30.06 |
| Indicator | SWX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 28.10 | 31.94 |
| Support Level | $81.21 | $19.39 |
| Resistance Level | $89.83 | $23.25 |
| Average True Range (ATR) | 1.54 | 1.16 |
| MACD | -0.44 | -0.44 |
| Stochastic Oscillator | 7.92 | 10.66 |
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.